🔍

AKUMS - Akums Drugs

📊 NSE: AKUMS 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 18:06

📢 Recent Corporate Announcements

Akums Subsidiary Acquires 4,050 Sq. Mtr Industrial Plot in Haridwar for Expansion

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 29 Apr 2026, 06:11 PM

Akums Drugs and Pharmaceuticals' wholly-owned subsidiary, Pure and Cure Healthcare Private Limited, has executed a lease deed for an industrial plot in Haridwar, Uttarakhand. The plot measures approximately 4,050 square meters and includes both land and building. This acquisition is strategically significant as the plot is adjacent to the subsidiary's existing manufacturing facility. The move is aimed at supporting and scaling up the company's business operations in the region.

Wholly-owned subsidiary Pure and Cure Healthcare executed a lease deed for a 4,050 Sq. Mtr industrial plot
The plot is located at IIE SIDCUL, Haridwar, adjacent to the subsidiary's existing manufacturing facility
The acquisition includes both land and building to support future business operations
The lease deed was executed on April 28, 2026, as per the regulatory filing

💡 Investors should view this as a positive operational expansion that could lead to increased production capacity. Monitor the company's upcoming capital expenditure plans to see how this facility will be integrated into their manufacturing workflow.

Akums Drugs Reaffirmed AA (Stable) Rating; New A1+ Assigned for Rs 200 Cr Commercial Paper

🟢 POSITIVE ⭐ 7/10

ROUTINE 📅 11 Apr 2026, 05:40 PM

ICRA has reaffirmed Akums Drugs and Pharmaceuticals' long-term rating at AA (Stable) and assigned a top-tier A1+ rating for its proposed Rs 200 crore commercial paper programme. The company maintains an exceptionally strong financial profile with a total debt-to-OPBDITA ratio of just 0.2x and cash reserves of Rs 1,654.4 crore as of September 2025. While the core CDMO business grew 7% YoY in 9M FY2026, the company continues to face margin pressure in its API and trade generics segments. A significant EUR 100 million upfront payment from a European contract has further bolstered liquidity.

ICRA reaffirmed AA (Stable)/A1+ ratings and assigned a new A1+ rating for Rs 200 crore Commercial Paper.
Strong liquidity position with cash and equivalents of Rs 1,654.4 crore against a minimal debt of Rs 90.3 crore.
CDMO segment generated Rs 2,533 crore in 9M FY2026, benefiting from 11% volume growth.
Total Debt/OPBDITA stands at a healthy 0.2 times with an interest coverage ratio of 5.3 times.
Company received EUR 100 million upfront as part of a EUR 200 million long-term contract with a European customer.

💡 The reaffirmed high credit rating and robust cash position confirm the company's financial stability and low default risk. Investors should monitor the scale-up of the export business and the potential turnaround of the loss-making API segment.

Akums Drugs Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Mar 2026, 12:56 PM

Akums Drugs and Pharmaceuticals Limited has notified the exchanges that its trading window will be closed starting April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's Q4 and full-year financial results for the period ending March 31, 2026. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the audited financial results are declared. The specific date for the Board meeting to approve these results will be communicated at a later date.

Trading window closure commences on April 1, 2026, for all designated persons.
Closure is related to the audited financial results for the quarter and year ending March 31, 2026.
The window will reopen 48 hours after the official declaration of the financial results.
The announcement follows SEBI's Prohibition of Insider Trading Regulations and the company's internal Code of Conduct.

💡 This is a routine regulatory filing with no direct impact on stock fundamentals; investors should wait for the upcoming announcement of the Q4 and FY26 earnings date.

Akums Drugs to Participate in Bharat Connect Conference on March 10, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Feb 2026, 12:49 PM

Akums Drugs and Pharmaceuticals Limited has scheduled a virtual group meeting with investors at the Bharat Connect Conference. The meeting is set for March 10, 2026, to engage with analysts and institutional investors. The company clarified that no unpublished price sensitive information will be discussed during this session. This interaction is part of the company's regular investor relations activities following SEBI regulations.

Participation in the Bharat Connect Conference scheduled for March 10, 2026.
The meeting will be conducted in a virtual group format for analysts and institutional investors.
Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Explicit statement that no unpublished price sensitive information (UPSI) will be shared during the conference.

💡 Investors should monitor the company's website or exchange filings for any investor presentations released following the conference to gain insights into management's outlook.

Akums Q3 FY26 Revenue Up 14.8% to ₹1,160 Cr; CDMO Segment Grows 16.3%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 19 Feb 2026, 10:29 AM

Akums Drugs and Pharmaceuticals reported a strong Q3 FY26 with operating revenue rising 14.8% YoY to INR 1,160 crores, primarily driven by a 16.3% growth in its core CDMO business. EBITDA grew 21% YoY to INR 147 crores, with margins expanding to 12.7% despite continued pricing pressure in the API segment. The company maintains a massive cash surplus of INR 1,573 crores and is actively evaluating M&A opportunities to complement its existing business. International branded formulations showed significant recovery, growing 120% sequentially to INR 50 crores.

Consolidated revenue increased 14.8% YoY to INR 1,160 crores, with CDMO revenue reaching INR 916 crores.
Operating EBITDA rose 21% YoY to INR 147 crores, while PAT stood at INR 68 crores after a one-time labour code impact of INR 18.2 crores.
International branded formulation revenue surged 120% QoQ to INR 50 crores due to demand recovery in key markets.
Maintained a strong liquidity position with a cash surplus of INR 1,573 crores and free cash flow of INR 944.5 crores.
European expansion is on track with EU GMP accreditation received for Plant 2 and supplies already commenced from Plant 1.

💡 Investors should monitor the company's deployment of its INR 1,573 crore cash pile for strategic acquisitions and the ramp-up of its European CDMO operations. The stock remains a strong play on the domestic outsourcing theme given its robust volume growth and margin expansion in the core CDMO segment.

Akums Drugs Q3 FY26 Revenue Up 14.8% to ₹1,160 Cr; CDMO Segment Grows 16.3%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 19 Feb 2026, 10:18 AM

Akums Drugs reported a strong Q3 FY26 with operating revenue reaching ₹1,160 crores, a 14.8% YoY increase, primarily driven by 16.3% growth in the core CDMO segment. EBITDA grew 21% YoY to ₹147 crores, with margins improving to 12.7% despite continued pricing pressure in the API business. The company maintains a robust cash surplus of ₹1,573 crores and is progressing on international expansions, including EU GMP accreditation for its oral liquids facility. Profit after tax stood at ₹68 crores, which includes a one-time labor code impact of ₹18.2 crores.

Consolidated revenue grew 14.8% YoY to ₹1,160 crores, led by double-digit volume growth in CDMO.
EBITDA increased 21% YoY to ₹147 crores with margins expanding 65 bps to 12.7%.
CDMO segment revenue reached ₹916 crores, while API losses narrowed sequentially to ₹7 crores.
Company holds a significant cash surplus of ₹1,573 crores and generated free cash flow of ₹944.5 crores.
Plant 2 received EU GMP accreditation; European supplies for a major contract are expected to start in FY28.

💡 Investors should focus on the company's ability to deploy its ₹1,573 crore cash surplus for inorganic growth and the upcoming ramp-up of international projects. The core CDMO business remains robust, and the narrowing of API losses suggests improving operational efficiency.

Akums Drugs Releases Audio Recording of Q3 FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 16 Feb 2026, 02:58 PM

Akums Drugs and Pharmaceuticals Limited has made the audio recording of its Q3 FY26 earnings conference call available to the public. The call, held on February 16, 2026, discussed the company's un-audited financial results for the quarter ended December 31, 2025. This disclosure is part of the mandatory regulatory requirements under SEBI Listing Obligations. Investors can access the recording via the company's website to hear management's detailed commentary on quarterly performance.

Audio recording of the Q3 FY26 earnings call held on February 16, 2026, is now accessible.
The call addressed the un-audited financial performance for the third quarter of the 2025-26 fiscal year.
A formal written transcript of the proceedings will be released and uploaded to the exchange in due course.
The recording provides direct access to management's responses to analyst queries regarding business outlook.

💡 Investors should review the audio recording or the upcoming transcript to understand management's perspective on margin trends and growth drivers. This is a routine but essential step for fundamental analysis following the quarterly results.

Akums Drugs to Host Virtual Group Investor Meet on February 19, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Feb 2026, 05:45 PM

Akums Drugs and Pharmaceuticals Limited has scheduled a virtual group investor meeting for February 19, 2026. The session is set to take place from 11:30 AM to 12:30 PM IST. This disclosure is a routine filing under Regulation 30 of SEBI (LODR) Regulations, 2015. The company has clarified that no unpublished price sensitive information will be shared during this interaction.

Virtual group meeting scheduled for February 19, 2026, at 11:30 AM IST.
The meeting is expected to last for approximately one hour.
Compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Explicit confirmation that no unpublished price sensitive information (UPSI) will be disclosed.
Information is being updated on the company's official website for public access.

💡 No immediate action is required as this is a routine meeting schedule. Investors may monitor the company's website for post-meet transcripts or presentations to understand management's outlook.

Akums Q3 FY26: Revenue Up 14.8% YoY to Rs 1,160 Cr, Adj PAT Jumps 29.5%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 05:34 PM

Akums Drugs and Pharmaceuticals reported a robust Q3 FY26 performance with revenue increasing 14.8% YoY to Rs 1,160 crore. The core CDMO business grew over 16% while Adjusted EBITDA rose 21% to Rs 147 crore, reflecting improved capacity utilization and margin expansion to 12.7%. Adjusted PAT saw a significant jump of 29.5% YoY to Rs 86 crore. Additionally, the company secured key regulatory approvals from EU GMP and UK MHRA, strengthening its position for expansion into regulated global markets.

Revenue increased 14.8% YoY to Rs 1,160 Cr, driven by strong CDMO volumes and international demand.
Adjusted EBITDA grew 21% YoY to Rs 147 Cr, with margins improving to 12.7% from 12.0% in Q3 FY25.
Adjusted PAT surged 29.5% YoY to Rs 86 Cr, while 9M FY26 PAT reached Rs 193 Cr.
Secured EU GMP certifications for two facilities and first UK MHRA approval for Rivaroxaban tablets.
International branded formulation segment revenue more than doubled on a sequential basis.

💡 The strong earnings growth and regulatory breakthroughs in regulated markets like the EU and UK are positive indicators. Investors should monitor the company's ability to maintain this momentum in international markets and the turnaround in the API segment.

Akums Drugs Q3 Standalone Revenue Up 18% Q-o-Q to ₹3,656M; PAT Declines 31% Y-o-Y

🔵 WATCH ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 04:03 PM

Akums Drugs and Pharmaceuticals reported a standalone revenue of ₹3,656.06 million for Q3 FY26, showing a healthy sequential growth of 18.2% from Q2. However, Net Profit (PAT) at ₹281.14 million declined by 31.7% year-on-year, impacted by rising expenses and an exceptional loss of ₹38.08 million. The company has successfully utilized 100% of its ₹6,373.70 million IPO proceeds for debt repayment and working capital. Investors should remain cautious regarding the ongoing Income Tax search proceedings, which are yet to reach a final conclusion.

Standalone Revenue from operations grew 18.2% Q-o-Q to ₹3,656.06 million.
Net Profit (PAT) stood at ₹281.14 million, down from ₹411.68 million in the same quarter last year.
Reported an exceptional item loss of ₹38.08 million during the quarter ended December 2025.
Total expenses increased to ₹3,585.35 million compared to ₹3,063.58 million in Q3 FY25.
IPO proceeds of ₹6,373.70 million have been fully utilized as of December 31, 2025.

💡 Investors should monitor the company's ability to recover margins which have seen year-on-year compression despite revenue growth. The ongoing Income Tax department's search and seizure proceedings remain a key regulatory risk to track.

Akums Drugs to Host Q3 FY26 Earnings Conference Call on February 16, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 31 Jan 2026, 03:19 PM

Akums Drugs and Pharmaceuticals Limited has scheduled its earnings conference call for the third quarter of FY26 on February 16, 2026, at 12:00 PM IST. The call will discuss the company's un-audited financial results for the period ending December 31, 2025. Key management personnel, including Managing Directors Sanjeev Jain and Sandeep Jain, and CFO Sumeet Sood, will be present to address analyst queries. The session is being moderated by Ambit Capital and includes international dial-in facilities for global investors.

Earnings call for Q3 FY26 scheduled for February 16, 2026, at 12:00 PM IST.
Participation from top management including both Managing Directors and the Chief Financial Officer.
The call will cover un-audited financial performance for the quarter ended December 31, 2025.
International access provided via toll-free numbers for Singapore, Hong Kong, USA, and UK.
Event hosted and moderated by Ambit Capital Institutional Equities.

💡 Investors should monitor the financial results release prior to the call and listen in for management commentary on CDMO segment growth and margin sustainability.

Akums Drugs Secures EU-GMP Certification for Two Haridwar Facilities; Valid Until 2028

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 23 Jan 2026, 04:54 PM

Akums Drugs and Pharmaceuticals has received European GMP certifications for its Plant 1 and Plant 2 located in Haridwar from the Bulgarian Drug Agency. Plant 1 received a renewal, while Plant 2 achieved its first-ever EU-GMP certification, both valid for three years until October 2028. This milestone allows the company to export tablets, capsules, and oral liquids to EU-regulated markets and other regions following similar standards. Crucially, Plant 2 will now begin servicing a European CDMO contract that was signed in December 2024.

EU-GMP certification granted by Bulgarian Drug Agency for two Haridwar-based manufacturing plants.
Plant 1 certification is a renewal, while Plant 2 receives its first-time EU-GMP approval.
Certifications are valid for a 3-year period, expiring in October 2028.
Plant 2 will service the European CDMO contract signed by the company in December 2024.
Enables supply of tablets, capsules, sachets, and oral liquid formulations to EU regulated markets.

💡 This is a positive development that expands the company's addressable market and validates its manufacturing standards for high-margin exports. Investors should monitor the execution of the December 2024 CDMO contract as a key revenue driver.

Akums Drugs Submits SEBI Regulation 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 04:44 PM

Akums Drugs and Pharmaceuticals Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Registrar MUFG Intime India Private Limited, confirms that all dematerialization requests for the quarter ended December 31, 2025, were processed within the prescribed timelines. It further verifies that security certificates were mutilated and cancelled after due verification. This is a standard procedural filing required for all listed entities in India to ensure the integrity of the shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025
Issued by Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited
Confirms that securities received for dematerialization were listed on the stock exchanges
Confirms that the register of members has been updated with depository names within timelines
Verification and cancellation of physical certificates completed as per SEBI norms

💡 No action is required as this is a routine regulatory filing. Investors should monitor the company's upcoming quarterly financial results for material performance indicators.

Akums Drugs President – Finance Rajkumar Bafna Resigns Effective Dec 31, 2025

🔵 WATCH ⭐ 6/10

MANAGEMENT 📅 27 Dec 2025, 04:32 PM

Akums Drugs and Pharmaceuticals Limited has announced the resignation of Mr. Rajkumar Bafna from his position as President – Finance, a Senior Management Personnel role. The resignation is effective from the close of business hours on December 31, 2025. Mr. Bafna cited personal health concerns specifically related to Delhi's pollution levels as the reason for his departure. The company has accepted the resignation and is managing the transition of his responsibilities.

Mr. Rajkumar Bafna, President – Finance, to step down effective December 31, 2025.
The resignation was formally tendered on December 3, 2025, and accepted by the company on December 12, 2025.
Departure is attributed to personal health issues linked to environmental conditions in Delhi.
Mr. Bafna is categorized as Senior Management Personnel (SMP) under SEBI Listing Regulations.

💡 Investors should monitor the company's upcoming announcements regarding the appointment of a successor to ensure continuity in financial leadership. The clear personal reason provided for the resignation mitigates concerns regarding internal corporate governance issues.

Akums Drugs to Close Trading Window from Jan 1, 2026, for Q3 FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Dec 2025, 10:48 AM

Akums Drugs and Pharmaceuticals Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI insider trading regulations. This closure is ahead of the declaration of the company's un-audited financial results for the quarter ending December 31, 2025. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be communicated at a later date.

Trading window closure begins on January 1, 2026, for all designated persons.
The closure pertains to the un-audited financial results for the quarter ending December 31, 2025.
Trading restrictions will be lifted 48 hours after the official announcement of the financial results.
The date for the Board of Directors meeting to approve the results is yet to be announced.

💡 This is a routine regulatory announcement and does not impact the company's fundamentals. Investors should monitor for the upcoming board meeting date to prepare for the Q3 financial performance update.

View All AKUMS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Domestic branded formulations grew 5.3% YoY to INR 122 Cr in Q2 FY26. International branded formulations declined 14.3% YoY to INR 22 Cr. API revenue declined 25.4% YoY to INR 44 Cr from INR 59 Cr as the company shifted focus toward higher-margin molecules.

Geographic Revenue Split

Domestic market remains the primary contributor; exports contribute 3.5% of total turnover. The company serves 72 international countries through subsidiaries like Akumentis and Unosource.

Profitability Margins

CDMO gross margins improved to 37.6% in Q2 FY26 compared to 37.1% in FY25. However, operating EBITDA declined 22% YoY due to operating deleverage and fixed overheads from new facilities.

EBITDA Margin

Domestic branded EBITDA margin improved significantly, with EBITDA rising 28.2% YoY to INR 26 Cr. International branded EBITDA grew 52% YoY to INR 5.5 Cr despite revenue declines, reflecting better product mix.

Capital Expenditure

Planned capex of INR 200-250 Cr per annum between FY2025 and FY2027. This is primarily directed toward the development of the Jammu manufacturing unit and regular maintenance/replacement capex.

Credit Rating & Borrowing

Credit ratings reaffirmed at [ICRA]AA (Stable) for long-term and [ICRA]A1+ for short-term. The company utilized INR 680 Cr from IPO proceeds for deleveraging, significantly improving debt protection metrics.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) and granules are primary raw materials. Specific percentage of total cost not disclosed, but falling API prices impacted margins for competitors more than Akums due to its diversified portfolio.

Capacity Expansion

Current combined production capacity is 49.6 billion units per annum across 12 formulation units. Planned expansion includes the Jammu plant, with commercial production expected to commence in 2026-27.

Raw Material Costs

Raw material costs are managed by focusing on high-margin molecules in the API segment. CDMO gross margins were maintained at 37.6% despite volume growth of 4-7% in Q2 FY26.

Manufacturing Efficiency

Three new injectable plants operationalized in H1 FY26 had a temporary negative EBITDA impact of INR 17 Cr due to ramp-up costs, regulatory approvals, and client audits.

Logistics & Distribution

Distribution is handled through a network of distributors and retail pharmacy outlets across India to ensure widespread availability.

📈 Strategic Growth

Growth Strategy

Growth will be driven by the 2026-27 Jammu plant launch, a newly formed Zambia JV, and targeted expansion into European markets starting 2027. The company is also pursuing inorganic growth using its INR 1,600 Cr net cash position, targeting profit-making businesses with export or dosage form capabilities.

Products & Services

Pharmaceutical formulations across 60 dosage forms, including tablets, capsules, and injectables; testing, development, and job work services.

Brand Portfolio

Akumentis, Unosource, Akums Healthcare UK Limited.

New Products/Services

Commercialization of over 4,000 formulations. New injectable facilities are currently ramping up and seeking regulatory approvals for future revenue contribution.

Market Expansion

Expansion into the UK via Akums Healthcare UK Limited (incorporated March 2025) and the European market with supply expected to commence in 2027.

Market Share & Ranking

Leading contract manufacturer with a 30.2% value share of the Indian domestic CDMO market and a 10.0% share of the total addressable Indian domestic CDMO market.

Strategic Alliances

Formed a Joint Venture in Zambia to strengthen international presence; maintains manufacturing relationships with over 1,448 trademarks.

🌍 External Factors

Industry Trends

The Indian CDMO market is growing, with Akums holding a 30.2% share. The industry is shifting toward specialized dosage forms and regulated market exports (Europe/UK).

Competitive Landscape

Competes with other CDMO players and API manufacturers; management notes that Akums' diversified portfolio provides better margin stability than concentrated competitors during API price drops.

Competitive Moat

Moat is built on massive scale (49.6 billion units), deep client relationships with top-tier pharma companies, and a large portfolio of 927 DCGI approvals and 1,448 trademarks.

Macro Economic Sensitivity

Performance is tied to the sustained long-term demand for outsourced drug development and manufacturing (CDMO).

Consumer Behavior

Increased reliance by major pharmaceutical companies on outsourced manufacturing to optimize their own supply chains.

Geopolitical Risks

International operations in 72 countries and 60+ export destinations expose the company to global trade and regulatory shifts.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to DCGI approvals (927 held) and international regulatory audits for new injectable facilities to permit exports to regulated markets.

Environmental Compliance

Exposed to tightening environmental regulations; breaches in waste or pollution norms could lead to increased operating costs.

Legal Contingencies

Income Tax department conducted searches at certain offices and manufacturing units in January 2025. The company is also monitoring compliance through a dedicated internal tool.

⚠️ Risk Analysis

Key Uncertainties

Ramp-up time for new injectable facilities and the timing of regulatory approvals for European exports (expected 2027) could impact short-term profitability.